Solvay To Co-Promote Wyeth’s Effexor XR With 120 Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the agreement, Wyeth will co-develop four mental health products from Solvay’s pipeline, including bifeprunox, an atypical antipsychotic in Phase III.
You may also be interested in...
Wyeth Says Bifeprunox Side Effect Profile Is Benefit Over Atypical Antipsychotics
NDA submission buoyed by four Phase III studies, including two involving active comparators.
Wyeth Says Bifeprunox Side Effect Profile Is Benefit Over Atypical Antipsychotics
NDA submission buoyed by four Phase III studies, including two involving active comparators.
Wyeth Set To File NDA For Antipsychotic Bifeprunox In 2006
Wyeth has partnered with Solvay to structure a development plan for the atypical antipsychotic.